EP1458249A1 - Food supplement for animals - Google Patents

Food supplement for animals

Info

Publication number
EP1458249A1
EP1458249A1 EP02805795A EP02805795A EP1458249A1 EP 1458249 A1 EP1458249 A1 EP 1458249A1 EP 02805795 A EP02805795 A EP 02805795A EP 02805795 A EP02805795 A EP 02805795A EP 1458249 A1 EP1458249 A1 EP 1458249A1
Authority
EP
European Patent Office
Prior art keywords
food supplement
composition
extract
animals
eucalyptus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02805795A
Other languages
German (de)
French (fr)
Inventor
Thierry Picaud
Amaury Greuter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytosynthese
Original Assignee
Phytosynthese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytosynthese filed Critical Phytosynthese
Publication of EP1458249A1 publication Critical patent/EP1458249A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • the invention relates to a complementary feed intended for animals, in particular ruminants, poultry, rabbits and pigs. It also relates to the use of said food supplement for the manufacture of a composition intended for the curative or preventive treatment of coccidiosis of ruminants, poultry, rabbits and pigs.
  • Coccidiosis is a parasitic pathology affecting the animal, and in particular the aforementioned animals, which can develop suddenly or evolve over several weeks.
  • the offending parasite is called coccidia or Eimeria, and the pathogenic or non-pathogenic species differ depending on the animal.
  • the parasite's life cycle is perfectly known and particularly complex and takes place mainly, partly in the external environment and partly in the intestine of the infected animal.
  • the symptoms observed correspond to a digestive syndrome with enteritis, often hemorrhagic.
  • acute coccidiosis can lead, in some cases, to the rapid death of the animal.
  • a first type of treatment consists of the administration of antibiotics.
  • Document FR-A-2 356 667 describes, for example, the preparation of an antibiotic for the treatment and prevention of coccidiosis in poultry, prepared from Streptomyces.
  • the antibiotic described in document WO-93/12800 is an antibiotic based on polycyclic acid ether obtained by fermentation of a microorganism called Actinomadura.
  • Other antibiotics are also described, for example in documents EP-A-15,110, EP-A-63,238, or even EP-A-255,335.
  • Another treatment consists in potentiating the immune functions of the animal by administration of an immunopotentializing and anti-infectious agent obtained by mixing several bacilli. Such a method is for example described in documents WO-94 / 22,459 or also WO-99 / 43,348.
  • Document EP-A-47 662 describes, for its part, another type of treatment consisting of a vaccine obtained from an attenuated strain of Eimeria necatrix.
  • document HU-A-96 02190 describes a food supplement for the treatment and prevention of coccidiosis of the hen containing essentially garlic.
  • Document EP-A-0 835 120 describes a pharmaceutical composition used in particular for the treatment of coccidiosis in poultry comprising a combination of thymol and carvacrol obtained from essential oil of oregano.
  • Document JP 07046963 describes a food composition intended for the prevention and treatment of coccidiosis containing terpenes, such as perrialldehyde, citral, bomeol, or terpenes originating from eucalyptus oil or clove oil.
  • terpenes such as perrialldehyde, citral, bomeol, or terpenes originating from eucalyptus oil or clove oil.
  • the document GB-A-2 321 583 describes a food to be chewed or licked by the animal based on a mixture of molasses and calcium, the mixture possibly also comprising herbs, such as in particular Fenugreek.
  • Document FR-A-2 582 485 describes a composition for supplementing and balancing animal nutrition, based on fish, yeast, vegetable oil and a phytotherapeutic complex of plants, among which boldo is mentioned in particular.
  • the invention relates to a food supplement intended for the animal which is characterized in that it contains, as a mixture, an eucalyptus extract, a fenugreek extract and an extract of boldo.
  • the eucalyptus extract belongs to the "globulus" variety.
  • the extract of eucalyptus leaves is in the form of an essential oil representing between 8 and 15% by weight of the supplement, advantageously between 9 and 13%.
  • the essential oil of Eucalyptus is obtained by distillation by steam entrainment of the leaves of Eucalyptus globulus.
  • Fenugreek extract is obtained from the seed and is in the form of a powder, which in practice represents between 10 and 30% by weight of the food supplement, preferably between 12 and 20%.
  • Fenugreek belongs to the legume family and produces yellow seeds containing an essential oil with a very bitter, marked odor, known under the name triogonelline.
  • the seed is also very rich in lecithin, nucleoalbumin, iron, in a very quickly assimilated form.
  • Fenugreek also has the advantage of being included in the GRAS (Generally Reconise As Safe) plant list of the American Federal Regulatory Code.
  • said food supplement also contains an extract of boldo leaf used for its positive action on digestion, which in practice represents from 10 to 20%, advantageously between 11 and 17%. by weight of the food supplement.
  • the boldo leaves come from a shrub called "Pneumus boldus", the leaves of which contain a small amount of boldine. The leaves are crushed to form a yellow-green powder, with strong aromatic odors and flavors.
  • the food supplement also contains a pharmaceutically acceptable excipient, in particular a powder coming from molding.
  • the food supplement of the invention can be incorporated into the animal's food in practice at a rate of 1 to 6 kg per tonne of complete food, ie:
  • the food supplement of the invention was very effective in the treatment of coccidiosis in a number of animals.
  • the invention also relates to the use of the food supplement as previously described for the manufacture of a composition intended for the preventive or curative treatment of coccidiosis of ruminants, poultry, rabbits and pigs.
  • the amount of essential oil of eucalyptus administered is between 0.7. 0.15 g / 100 kg body fat for poultry, pigs, rabbits; 0.5 to 0.7 g / 100 kg of body fat for ruminants.
  • the quantity of essential oil administered to the animal is between 0.10 and 0.3 g / 100 kg of body weight for poultry, pigs and rabbits; 0.7 to 0.15 g / 100 kg of body fat for ruminants.
  • FIG. 1 represents the ookystal excretion at the duodenal (la) or caecal (lb) level before and after treatment with the composition of the invention.
  • the essential oil is first absorbed on molding (manufacture of a premix). The other ingredients are then added.
  • the objective is to determine the anticoccidial activity of the phytotherapeutic product of the invention (product A) in a treatment against the infestation of coccidia in sheepfolds.
  • the experimental animals are 77 cross-breed lambs (cross breed x Charolais sheep) born from the end of October to mid-November from the same farm. They are raised in sheepfolds, with their mother, breastfed for three months, then weaned and fattened. 2 - Treatment
  • Control lot 34 lambs are kept without anticoccidial treatment until sale (12 single lambs, 22 twin lambs and 17 males, 17 females).
  • Invention Lot 33 lambs receive product A about 10 days after birth until sale, at a dosage of 6g / 100 kg bodyweight / day, or 2 kg / tomie of feed.
  • the phytotherapeutic product is incorporated into the self-service lamb food (13 single lambs, 20 twin lambs and 15 males, 18 females).
  • Anticoccidial excretion was quantified by individual coproscopic examinations (Calamel-Soulé technique) from droppings on 15 lambs from each batch (the same at each control). The exams are carried out on D0, D21 and D45. An identification of the coccidia species is carried out on the mixture of faeces from each batch.
  • the anticoccidial efficiency is calculated on the geometric mean according to the following principle:
  • the excretion is 306.2 coccidial oocysts per gram (o.p.g.) in the control batch and 418 o.p.g. in lot A.
  • o.p.g. coccidial oocysts per gram
  • 418 o.p.g. in lot A.
  • Product A has anticoccidial activity.
  • the antiparasitic efficacy is 99.6% on D21 and 96.1% on D45 on the reduction of excretion (Table I). This anticoccidial activity has reduced the number of shedding lambs.
  • the efficiency is 60% at D21, and 30% at D45 (Table II).
  • Table III Zootechnical balance after control of coccidia with Lot A
  • Table IV weight gain in Lot A
  • Table V This trend is observed in Lot A lambs intended for slaughter, with a 1.3% higher growth and a reduced breeding time of 13.2% (Table V).
  • the anti-coccidial activity of the composition of the invention was evaluated on 22,000 chickens suffering from coccidiosis, the treatment being carried out over 3 days at a rate of 1 ml.
  • Figures 1a and 1b show the duodenal ( Figure 1a) and caecal ookystal excretions ( Figure 1b).
  • the present study shows the effectiveness of the composition of the invention compared to a chemical control composition (monensin) on the growth of two lots of chickens.
  • composition of the invention is administered at a rate of 1.5 kg per tonne.
  • results are reproduced in Tables VI and VII below.
  • composition of the invention 38 229 82.36 26.36 '.04 2, 171
  • the average daily gain in grams of a chicken treated with the composition of the invention is improved compared to the chemical control anticoccidial.
  • the performance index resulting from the combination of the various factors, in particular average daily gain, consumption index and chicken per m 2 is improved.
  • This test is carried out under the same conditions by administering to four batches of chickens, 2 kg of the composition of the invention per tonne.
  • Example 3 Synergistic action of eucalyptus, fenugreek and boldo
  • This example aims to demonstrate the improvement in the treatment efficiency of coccidiosis obtained by the mixture of the invention with regard to a simple eucalyptus extract.
  • nitrates The measurement of nitrates is indicative of the reactivity of the macrophages. It indirectly characterizes the immune reaction of animals and therefore their defense. The lower the nitrate level, the less the inflammatory reaction is important.
  • Each poultry is infested with 1,000 oocysts of E. acervidina and 1,000 oocysts of E. tenella.
  • the compositions tested are the following: A: eucalyptus essential oil B: composition of the invention (Example 1) U: no treatment V: no infection
  • composition of the invention provides an improvement over eucalyptus alone.
  • Poultry are infected with large doses of oocysts (10,000
  • E. acervulena + 10,000 E. tenella The number of oocysts excreted after 5 to 8 days of infection is measured.
  • composition of the invention is particularly effective on the excretion of oocysts.

Abstract

The invention concerns an a food supplement for animals, characterized in that it contains in a mixture: a eucalyptus extract, a fenugreek extract, a boldo extract.

Description

COMPLEMENT ALIMENTAIRE DESTINE A L'ANIMAL FOOD SUPPLEMENT FOR ANIMALS
L'invention concerne un aliment complémentaire destiné à l'animal, en particulier, les ruminants, volailles, lapins et porcs. Elle se rapporte également à l'utilisation dudit complément alimentaire pour la fabrication d'une composition destinée au traitement curatif ou préventif de la coccidiose du ruminant, volaille, lapin et porc.The invention relates to a complementary feed intended for animals, in particular ruminants, poultry, rabbits and pigs. It also relates to the use of said food supplement for the manufacture of a composition intended for the curative or preventive treatment of coccidiosis of ruminants, poultry, rabbits and pigs.
La coccidiose est une pathologie parasitaire touchant l'animal, et en particulier les animaux précités, qui peut se développer brutalement ou évoluer sur plusieurs semaines. Le parasite incriminé est dénommé coccidie ou encore Eimeria, et les espèces pathogènes ou non pathogènes diffèrent en fonction de l'animal. Le cycle évolutif du parasite est parfaitement connu et particulièrement complexe et se déroule pour l'essentiel, en partie dans le milieu extérieur et en partie dans l'intestin de l'animal infecté. Les symptômes observés correspondent à un syndrome digestif avec entérite, souvent hémorragique. En outre, la coccidiose aiguë peut conduire, dans certains cas, à la mort rapide de l'animal.Coccidiosis is a parasitic pathology affecting the animal, and in particular the aforementioned animals, which can develop suddenly or evolve over several weeks. The offending parasite is called coccidia or Eimeria, and the pathogenic or non-pathogenic species differ depending on the animal. The parasite's life cycle is perfectly known and particularly complex and takes place mainly, partly in the external environment and partly in the intestine of the infected animal. The symptoms observed correspond to a digestive syndrome with enteritis, often hemorrhagic. In addition, acute coccidiosis can lead, in some cases, to the rapid death of the animal.
De nombreux traitements ont été proposés pour traiter cette pathologie.Many treatments have been proposed to treat this pathology.
Ainsi, par exemple, un premier type de traitement consiste en l'administration d'antibiotiques. Le document FR-A-2 356 667 décrit par exemple la préparation d'un antibiotique pour le traitement et la prévention de la coccidiose des volailles, préparé à partir de Streptomyces. L'antibiotique décrit dans le document WO-93/12800 est un antibiotique à base d'éther d'acide polycyclique obtenu par fermentation d'un microorganisme dénommé Actinomadura. D'autres antibiotiques sont également décrits, par exemple dans les documents EP-A-15 110, EP-A-63 238, ou encore EP-A-255 335. Un autre traitement consiste à potentialiser les fonctions immunes de l'animal par administration d'un agent immunopotentialisateur et anti-infectieux obtenu par mélange de plusieurs bacilles. Une telle méthode est par exemple décrit dans les documents WO-94/22 459 ou encore WO-99/43 348.Thus, for example, a first type of treatment consists of the administration of antibiotics. Document FR-A-2 356 667 describes, for example, the preparation of an antibiotic for the treatment and prevention of coccidiosis in poultry, prepared from Streptomyces. The antibiotic described in document WO-93/12800 is an antibiotic based on polycyclic acid ether obtained by fermentation of a microorganism called Actinomadura. Other antibiotics are also described, for example in documents EP-A-15,110, EP-A-63,238, or even EP-A-255,335. Another treatment consists in potentiating the immune functions of the animal by administration of an immunopotentializing and anti-infectious agent obtained by mixing several bacilli. Such a method is for example described in documents WO-94 / 22,459 or also WO-99 / 43,348.
Certains documents décrivent par ailleurs des traitements par administration de molécules de synthèse telles que par exemple des purines (EP-A-76 127), des pyιτoles (WO-01/34 632), des dérivés de la riboflavine (FR-A-2 368 956)...Some documents also describe treatments by administration of synthetic molecules such as for example purines (EP-A-76 127), pyιτoles (WO-01/34 632), riboflavin derivatives (FR-A-2 368 956) ...
Le document EP-A-47 662 décrit, quant à lui, un autre type de traitement consistant en un vaccin obtenu à partir d'une souche atténuée de Eimeria necatrix.Document EP-A-47 662 describes, for its part, another type of treatment consisting of a vaccine obtained from an attenuated strain of Eimeria necatrix.
D'autres traitements consistent à administrer à l'animal une composition à base de plantes. Ainsi par exemple, le document HU-A-96 02190 décrit un complément alimentaire pour le traitement et la prévention de la coccidiose de la poule contenant essentiellement de l'ail. Le document EP-A-0 835 120 décrit une composition pharmaceutique utilisée notamment pour le traitement de la coccidiose de la volaille comprenant une association de thymol et carvacrol obtenue à partir d'huile essentielle d'origan.Other treatments consist in administering to the animal a herbal composition. Thus, for example, document HU-A-96 02190 describes a food supplement for the treatment and prevention of coccidiosis of the hen containing essentially garlic. Document EP-A-0 835 120 describes a pharmaceutical composition used in particular for the treatment of coccidiosis in poultry comprising a combination of thymol and carvacrol obtained from essential oil of oregano.
Le document JP 07046963 décrit une composition alimentaire destinée à la prévention et au traitement de la coccidiose contenant des terpènes, tels que perrialldéhyde, citral, boméol, ou terpènes provenant d'huile d'eucalyptus ou d'huile de clou de girofle.Document JP 07046963 describes a food composition intended for the prevention and treatment of coccidiosis containing terpenes, such as perrialldehyde, citral, bomeol, or terpenes originating from eucalyptus oil or clove oil.
Le document GB-A-2 321 583 décrit un aliment à croquer ou à lécher par l'animal à base d'un mélange de mélasse et de calcium, le mélange pouvant en outre comprendre des herbes, telles que notamment le Fenugrec. Le document FR-A-2 582 485 décrit une composition pour compléter et équilibrer l'alimentation animale, à base de poisson, de levure, d'huile végétale et d'un complexe phytotherapeutique de plantes parmi lesquelles est notamment cité le boldo.The document GB-A-2 321 583 describes a food to be chewed or licked by the animal based on a mixture of molasses and calcium, the mixture possibly also comprising herbs, such as in particular Fenugreek. Document FR-A-2 582 485 describes a composition for supplementing and balancing animal nutrition, based on fish, yeast, vegetable oil and a phytotherapeutic complex of plants, among which boldo is mentioned in particular.
Le Demandeur a découvert que, de manière tout à fait surprenante, l'association d'eucalyptus, de boldo et de fenugrec permettait de traiter tant en préventif qu'en curatif la coccidiose des volailles et des ruminants (veaux, agneaux, génisses, chevaux), lapins et porcs de façon plus efficace que l'huile d'eucalyptus seule.The Applicant has discovered that, quite surprisingly, the combination of eucalyptus, boldo and fenugreek made it possible to treat both preventive and curative coccidiosis of poultry and ruminants (calves, lambs, heifers, horses ), rabbits and pigs more effectively than eucalyptus oil alone.
En conséquence, l'invention concerne un complément alimentaire destiné à l'animal qui se caractérise en ce qu'il contient, en mélange, un extrait d'eucalyptus, un extrait de fenugrec et un extrait de boldo.Consequently, the invention relates to a food supplement intended for the animal which is characterized in that it contains, as a mixture, an eucalyptus extract, a fenugreek extract and an extract of boldo.
Dans une forme de réalisation avantageuse, l'extrait d'eucalyptus appartient à la variété "globulus".In an advantageous embodiment, the eucalyptus extract belongs to the "globulus" variety.
En pratique, l'extrait de feuilles d'eucalyptus se présente sous forme d'une huile essentielle représentant entre 8 et 15 % en poids du complément, avantageusement entre 9 et 13 %.In practice, the extract of eucalyptus leaves is in the form of an essential oil representing between 8 and 15% by weight of the supplement, advantageously between 9 and 13%.
De manière connue, l'huile essentielle d'Eucalyptus est obtenue par distillation par entraînement à la vapeur des feuilles d'Eucalyptus globulus.In known manner, the essential oil of Eucalyptus is obtained by distillation by steam entrainment of the leaves of Eucalyptus globulus.
L'extrait de fenugrec est obtenu à partir de la graine et se présente sous forme de poudre, laquelle représente en pratique entre 10 et 30 % en poids du complément alimentaire, préférentiellement entre 12 et 20 %. Le fenugrec appartient à la famille des légumineuses et produit des graines jaune contenant une huile essentielle à odeur marquée très amère, connue sous la dénomination triogonelline. La graine est en outre très riche en lécithine, nucléoalbumine, fer, sous forme très rapidement assimilable. Le fenugrec présente en outre l'avantage d'être inscrit dans la liste des plantes G.R.A.S. (Generally Reconise As Safe) du Code de Régulation Fédéral Américain.Fenugreek extract is obtained from the seed and is in the form of a powder, which in practice represents between 10 and 30% by weight of the food supplement, preferably between 12 and 20%. Fenugreek belongs to the legume family and produces yellow seeds containing an essential oil with a very bitter, marked odor, known under the name triogonelline. The seed is also very rich in lecithin, nucleoalbumin, iron, in a very quickly assimilated form. Fenugreek also has the advantage of being included in the GRAS (Generally Reconise As Safe) plant list of the American Federal Regulatory Code.
Pour limiter les phénomènes de mal absorption fréquente en cas de coccidiose, ledit complément alimentaire contient en outre un extrait de feuille de boldo employée pour son action positive sur la digestion, qui en pratique représente de 10 à 20 %, avantageusement entre 11 et 17 % en poids du complément alimentaire.To limit the phenomena of frequent poor absorption in case of coccidiosis, said food supplement also contains an extract of boldo leaf used for its positive action on digestion, which in practice represents from 10 to 20%, advantageously between 11 and 17%. by weight of the food supplement.
Les feuilles de boldo proviennent d'un arbrisseau dénommé "Pneumus boldus", dont les feuilles contiemient une faible quantité de boldine. Les feuilles sont broyées pour former une poudre de couleur vert jaune, d'odeurs et de saveurs aromatiques accentuées.The boldo leaves come from a shrub called "Pneumus boldus", the leaves of which contain a small amount of boldine. The leaves are crushed to form a yellow-green powder, with strong aromatic odors and flavors.
Pour compléter la composition en poids à 100 %, le complément alimentaire contient en outre un excipient pharmaceutiquement acceptable, notamment une poudre venue de remoulage.To complete the composition by weight at 100%, the food supplement also contains a pharmaceutically acceptable excipient, in particular a powder coming from molding.
Bien entendu, le complément alimentaire de l'invention peut être intégré à l'aliment de l'animal à raison en pratique de 1 à 6 kg par tonne d'aliment complet, soit :Of course, the food supplement of the invention can be incorporated into the animal's food in practice at a rate of 1 to 6 kg per tonne of complete food, ie:
- pour les volailles, porcs, lapins : 6 à 12 g/100 kg de poids vif (PV), pour les ruminants : 4 à 6 g/100 kg de PV. Comme déjà dit, le Demandeur a constaté que de manière tout à fait surprenante, le complément alimentaire de l'invention était très efficace dans le traitement de la coccidiose d'un certain nombre d'animaux.- for poultry, pigs, rabbits: 6 to 12 g / 100 kg bodyweight (PV), for ruminants: 4 to 6 g / 100 kg body weight. As already said, the Applicant has found that, quite surprisingly, the food supplement of the invention was very effective in the treatment of coccidiosis in a number of animals.
En conséquence, l'invention concerne également l'utilisation du complément alimentaire tel que précédemment décrit pour la fabrication d'une composition destinée au traitement préventif ou curatif de la coccidiose du ruminant, volaille, lapin et porc.Consequently, the invention also relates to the use of the food supplement as previously described for the manufacture of a composition intended for the preventive or curative treatment of coccidiosis of ruminants, poultry, rabbits and pigs.
Dans ce traitement, lorsque le complément alimentaire est utilisé pour une action préventive, la quantité d'huile essentielle d'eucalyptus administrée est comprise entre 0,7. à 0,15 g/100 kg de PV pour volailles, porcs, lapins ; 0,5 à 0,7 g/100 kg de PV pour les ruminants.In this treatment, when the food supplement is used for a preventive action, the amount of essential oil of eucalyptus administered is between 0.7. 0.15 g / 100 kg body fat for poultry, pigs, rabbits; 0.5 to 0.7 g / 100 kg of body fat for ruminants.
En revanche, lorsque le complément alimentaire est utilisé pour un traitement curatif, la quantité d'huile essentielle administrée à l'animal est comprise entre 0,10 et 0,3 g/100 kg de PV pour les volailles, porcs et lapins ; 0,7 à 0,15 g/ 100 kg de PV pour les ruminants.On the other hand, when the food supplement is used for a curative treatment, the quantity of essential oil administered to the animal is between 0.10 and 0.3 g / 100 kg of body weight for poultry, pigs and rabbits; 0.7 to 0.15 g / 100 kg of body fat for ruminants.
L'invention et les avantages qui en découlent ressortiront mieux des exemples de réalisation suivants à l'appui des figures annexées.The invention and the advantages which result therefrom will emerge more clearly from the following exemplary embodiments in support of the appended figures.
La figure 1 représente l'excrétion ookystale au niveau duodénal (la) ou caecal (lb) avant et après traitement par la composition de l'invention. FIG. 1 represents the ookystal excretion at the duodenal (la) or caecal (lb) level before and after treatment with the composition of the invention.
Exemple 1 : Préparation de la composition de l'inventionExample 1: Preparation of the composition of the invention
On prépare un complément alimentaire ayant la composition suivante (Merci de vérifier si cette formule correspond à celle de l'EIMERICOX) : - huile essentielle d'eucalyptus : 15 % extrait de boldo : 12 % graine de fenugrec : 15 % remoulage qsp : 100 %We prepare a food supplement with the following composition (Please check if this formula corresponds to that of EIMERICOX): - essential oil of eucalyptus: 15% boldo extract: 12% fenugreek seed: 15% molding qs: 100 %
L'huile essentielle est d'abord absorbée sur remoulage (fabrication d'un prémélange). Les autres ingrédients sont ensuite ajoutés.The essential oil is first absorbed on molding (manufacture of a premix). The other ingredients are then added.
Exemple 2 :Example 2:
a/ E F FIC A CITE CHEZ L 'A GNEA Ua / E F FIC A CITE AT L A A GNEA U
L'objectif est de déterminer l'activité anticoccidienne du produit phytothérapique de l'invention (produit A) dans un traitement contre l'infestation de coccidies chez des agneaux de bergerie.The objective is to determine the anticoccidial activity of the phytotherapeutic product of the invention (product A) in a treatment against the infestation of coccidia in sheepfolds.
Matériel et méthodeMaterial and method
1 - Animaux expérimentaux1 - Experimental animals
Les animaux expérimentaux sont 77 agneaux de race croisée (brebis race croisée x charolais) nés de fin octobre à mi-novembre d'un même élevage. Ils sont élevés en bergerie, avec leur mère, allaités pendant trois mois, puis sevrés et engraissés. 2 - TraitementThe experimental animals are 77 cross-breed lambs (cross breed x Charolais sheep) born from the end of October to mid-November from the same farm. They are raised in sheepfolds, with their mother, breastfed for three months, then weaned and fattened. 2 - Treatment
Deux lots d'agneaux sont constitués 10 jours après la naissance sur le poids, le sexe et le nombre d'individu par brebis.Two lots of lambs are made up 10 days after birth on the weight, sex and number of individuals per ewe.
Lot Témoin : 34 agneaux sont conservés sans traitement anticoccidien jusqu'à la vente (12 agneaux simples, 22 agneaux jumeaux et 17 mâles, 17 femelles).Control lot: 34 lambs are kept without anticoccidial treatment until sale (12 single lambs, 22 twin lambs and 17 males, 17 females).
Lot Invention : 33 agneaux reçoivent du produit A de 10 jours environ après la naissance jusqu'à la vente, à la posologie de 6g / 100 kg de poids vif /jour, soit 2 kg / tomie d'aliment. Le produit phytothérapique est incorporé à l'aliment distribué en libre service aux agneaux (13 agneaux simples, 20 agneaux jumeaux et 15 mâles, 18 femelles).Invention Lot: 33 lambs receive product A about 10 days after birth until sale, at a dosage of 6g / 100 kg bodyweight / day, or 2 kg / tomie of feed. The phytotherapeutic product is incorporated into the self-service lamb food (13 single lambs, 20 twin lambs and 15 males, 18 females).
3 - Contrôles3 - Controls
Contrôles parasitairesPest control
L'excrétion anticoccidienne a été quantifiée par examens coproscopiques individuels (technique Calamel-Soulé) à partir de prélèvements de crottes sur 15 agneaux de chaque lot (les mêmes à chaque contrôle). Les examens sont réalisés à J0, J21 et J45. Une identification des espèces de coccidies est effectuée sur le mélange des fèces de chaque lot.Anticoccidial excretion was quantified by individual coproscopic examinations (Calamel-Soulé technique) from droppings on 15 lambs from each batch (the same at each control). The exams are carried out on D0, D21 and D45. An identification of the coccidia species is carried out on the mixture of faeces from each batch.
L'efficacité anticoccidienne est calculée sur la moyenne géométrique selon le principe suivant :The anticoccidial efficiency is calculated on the geometric mean according to the following principle:
Nombre o.p.g. Jx lot Témoin - nombre o.p.g. Jx Lot A Nombre o.p.g. jx lot Témoin RESULTATSOpg number Jx witness batch - opg number Jx Lot A RESULTS
1 - Activité anticoccidienne1 - Anticoccidial activity
A J0, l'excrétion est de 306,2 ookystes de coccidies par gramme (o.p.g.) dans le lot Témoin et de 418 o.p.g. dans le lot A. Dans le lot Témoin, on note une excrétion de 18 146 o.p.g. à J21 et de 1 418 à J45 (moyenne arithmétique) qui concerne tous les agneaux du lot. Le produit A présente une activité anticoccidienne. L'efficacité antiparasitaire est de 99,6 % à J21 et de 96,1 % à J45 sur la réduction de l'excrétion (Tableau I). Cette activité anticoccidienne a réduit le nombre d'agneaux excréteurs. L'efficacité est de 60 % à J21, et de 30 % à J45 (Tableau II).At D0, the excretion is 306.2 coccidial oocysts per gram (o.p.g.) in the control batch and 418 o.p.g. in lot A. In the control lot, there is an excretion of 18,146 o.p.g. at D21 and from 1,418 to D45 (arithmetic mean) which concerns all the lambs in the lot. Product A has anticoccidial activity. The antiparasitic efficacy is 99.6% on D21 and 96.1% on D45 on the reduction of excretion (Table I). This anticoccidial activity has reduced the number of shedding lambs. The efficiency is 60% at D21, and 30% at D45 (Table II).
(1) Moyenne arithmétique(1) Arithmetic mean
(2) Moyenne géométrique(2) Geometric mean
(*) Calcul effectué sur la moyenne géométrique(*) Calculation performed on the geometric mean
Tableau I — Activité anticoccidienne de la composition de l'invention Table I - Anticoccidial activity of the composition of the invention
Tableau II— Activité anticoccidienne de la composition de l'inventionTABLE II Anticoccidial activity of the composition of the invention
Les résultats globaux sur la croissance des agneaux indiquent dans le Lot Témoin un gain de poids de 14,7 kg et une durée moyenne d'élevage de 105,9 jours. Dans le Lot A, le gain de poids est de 15,4 kg pour 85 jours d'élevage en moyenne. Le supplément de croissance est de 4,8 % et la réduction de la durée d'élevage est de 23,3 % par rapport au Lot Témoin (Tableau III).The overall results on lamb growth indicate in the Control Lot a weight gain of 14.7 kg and an average breeding time of 105.9 days. In Lot A, the weight gain is 15.4 kg for 85 days of aging on average. The growth supplement is 4.8% and the reduction in aging time is 23.3% compared to the control batch (Table III).
Tableau III— Bilan zootechnique après contrôle des coccidies avec le Lot A Sur les agnelles de renouvellement, on note une amélioration de 8,8 % du gain de poids dans le Lot A par rapport au Lot Témoin (Tableau IV). Cette tendance s'observe chez les agneaux du Lot A destinés à la boucherie, avec une croissance supérieure de 1,3 % et une durée d'élevage réduite de 13,2 % (Tableau V).Table III— Zootechnical balance after control of coccidia with Lot A On renewal ewe lambs, there is an 8.8% improvement in weight gain in Lot A compared to the Control Lot (Table IV). This trend is observed in Lot A lambs intended for slaughter, with a 1.3% higher growth and a reduced breeding time of 13.2% (Table V).
Tableau IV- Gain de poids des agnellesTable IV- Weight gain of ewe lambs
Tableau V - Gain de poids des agneaux de bergerie b/ E F FIC A CITE CHEZ LES VOLAILLESTable V - Weight gain of sheepfolds b / EF FIC A CITES IN POULTRY
1. Activité anti-coccidienne1. Anti-coccidial activity
L'activité anti-coccidienne de la composition de l'invention a été évaluée sur 22 000 poulets atteints de coccidiose, le traitement étant effectué sur 3 jours à raison de lml 1.The anti-coccidial activity of the composition of the invention was evaluated on 22,000 chickens suffering from coccidiosis, the treatment being carried out over 3 days at a rate of 1 ml.
Sur les figures la et lb, sont représentées les excrétions ookystales duodénale (figure la) et caecale (figure lb).Figures 1a and 1b show the duodenal (Figure 1a) and caecal ookystal excretions (Figure 1b).
Comme le montrent ces histogrammes, quel que soit le taux d'excrétion ookystale avant traitement (pavés gauches), on observe après 3 jours de traitement (pavés droits), une réduction nette de l'excrétion tant au niveau duodénal que caecal. ' As these histograms show, whatever the rate of ookystal excretion before treatment (left paving stones), after 3 days of treatment (right paving stones), a marked reduction in excretion is observed both at the duodenal and cecal level. '
2. Influence sur la croissance2. Influence on growth
a/ Etude en labela / Label study
La présente étude montre l'efficacité de la composition de l'invention par rapport à une composition témoin chimique (monensin) sur la croissance de deux .lots de poulets.The present study shows the effectiveness of the composition of the invention compared to a chemical control composition (monensin) on the growth of two lots of chickens.
Les paramètres pris en considération sont l'indice de performance et le gain moyen quotidien. La composition de l'invention est administrée à raison de 1,5 kg par tonne. Les résultats sont reproduits dans les tableaux VI et VII suivants.The parameters taken into account are the performance index and the average daily gain. The composition of the invention is administered at a rate of 1.5 kg per tonne. The results are reproduced in Tables VI and VII below.
Nombre Age en Gain Ec; art Poids Ecart Indice de d'animaux jours Moyen moyen performanceAge Gain Number Ec; art Weight Deviation Index of animals days Average medium performance
Quotidien en kg en gDaily in kg in g
Témoin 98 300 82,84 25,32 2,083 87Witness 98,300 82.84 25.32 2,083 87
+ SS g+ SS g
Composition de l'invention 38 229 82,36 26,36 ' .04 2, 171Composition of the invention 38 229 82.36 26.36 '.04 2, 171
8989
Tableau VITable VI
Nombre Age en Gain Ecart Poids Ecart Indice de d'animaux jours Moyen moyen performanceNumber Age in Gain Gap Weight Gap Index of animals days Average average performance
Quotidien en kg en gDaily in kg in g
Témoin 30 129 81 ,98 26,46 2, 169 95Witness 30 129 81, 98 26.46 2, 169 95
+ + 81 g+ + 81 g
Composition de l'invention 12 762 81 ,66 27,55 1 ,09 2,250 97Composition of the invention 12,762 81, 66 27.55 1.09 2,250 97
Tableau VIITable VII
Comme le montre cette étude, le gain moyen quotidien en grammes d'un poulet traité par la composition de l'invention est amélioré par rapport à l'anticoccidien témoin chimique. En outre, l'indice de performance résultant de la combinaison des différents facteurs, notamment gain moyen quotidien, indice de consommation et poulet au m2, est amélioré.As this study shows, the average daily gain in grams of a chicken treated with the composition of the invention is improved compared to the chemical control anticoccidial. In addition, the performance index resulting from the combination of the various factors, in particular average daily gain, consumption index and chicken per m 2 , is improved.
b/ Etude sur des poulets fermiers blancsb / Study on white farm chickens
Ce test est conduit dans les mêmes conditions en administrant à quatre lots de poulets, 2 kg de la composition de l'invention par tonne.This test is carried out under the same conditions by administering to four batches of chickens, 2 kg of the composition of the invention per tonne.
Les résultats figurent dans le tableau VIII suivant. Indice deThe results are shown in Table VIII below. Index
Nom e Age Gain Ecart Poids Ecart consomEcart d'animaux en Moyen moyen mation jours Quotidien en kg (quantité en g d'aliment pour obtenir 1 kg de poulet)Name e Age Gain Gap Weight Gap consumed Gap of animals in Average average days Daily in kg (quantity in g of feed to obtain 1 kg of chicken)
Moyenne Témoin 161 796 83, 12 25,46 2, 1 16 2,979 générale Composition 0,2S 0,016 -0,054 de l'invention 172 553 82,84 25,74 2, 132 2,925Average Witness 161 796 83, 12 25.46 2, 1 16 2.979 general Composition 0.2S 0.016 -0.054 of the invention 172 553 82.84 25.74 2.132 2.925
Moyenne Témoin 51 684 82,32 26,30 2,265 2,810 du 1 er tiers Composition -0,02 0,001 -0,027 de l'invention 58 651 82,43 26,28 2,166 2,763Average Witness 51,684 82.32 26.30 2.265 2.810 of the 1 st third Composition -0.02 0.001 -0.027 of the invention 58 651 82.43 26.28 2.166 2.763
Moyenne Témoin 55 584 83,64 25,48 2, 13 1 2,960 du 2è tiers Composition 0,48 0,034 -0.043 de l'invention 55 634 83,40 25,96 2,165 2,917Average Witness 55,584 83.64 25.48 2.13 1 2,960 of the 2nd third Composition 0.48 0.034 -0.043 of the invention 55 634 83.40 25.96 2.165 2.917
Moyenne Témoin 54 528 83,37 24,64 2,054 3,167 du 3è tiers Composition 0,34 0,012 -0,084 de l'invention 58 268 28,72 24,98 2,066 3,083Average Witness 54,528 83.37 24.64 2,054 3,167 in the third tier Composition 0.34 0.012 -0.084 of the invention 58,268 28.72 24.98 2,066 3,083
Tableau VIIITable VIII
Comme le montre ce tableau, le gain moyen quotidien de même que l'indice de consommation (IC) sont améliorés pour la composition de l'invention.As this table shows, the average daily gain as well as the consumption index (CI) are improved for the composition of the invention.
Exemple 3 : Action synergique de l'eucalyptus, fenugrec et boldoExample 3: Synergistic action of eucalyptus, fenugreek and boldo
Cet exemple vise à démontrer l'amélioration de l'efficacité de traitement de la coccidiose obtenue par le mélange de l'invention au regard d'un simple extrait d'eucalyptus.This example aims to demonstrate the improvement in the treatment efficiency of coccidiosis obtained by the mixture of the invention with regard to a simple eucalyptus extract.
a/ EVALUATION DU TAUX DE NITRATE 6 JOURS APRES INFECTIONa / EVALUATION OF THE NITRATE RATE 6 DAYS AFTER INFECTION
La mesure des nitrates est révélatrice de la réactivité des macrophages. Elle caractérise indirectement la réaction immunitaire des animaux et donc leur défense. Plus le taux de nitrate est faible, moins la réaction inflammatoire est importante. Les volailles sont infestées chacune par 1 000 oocystes de E. acervidina et 1 000 oocystes de E. tenella. Les compositions testées sont les suivantes : A : huile essentielle d'eucalyptus B : composition de l'invention (Exemple 1) U : pas de traitement V : pas d'infectionThe measurement of nitrates is indicative of the reactivity of the macrophages. It indirectly characterizes the immune reaction of animals and therefore their defense. The lower the nitrate level, the less the inflammatory reaction is important. Each poultry is infested with 1,000 oocysts of E. acervidina and 1,000 oocysts of E. tenella. The compositions tested are the following: A: eucalyptus essential oil B: composition of the invention (Example 1) U: no treatment V: no infection
Les résultats figurent dans le tableau suivant :The results are shown in the following table:
Composition Nb de Volailles Taux de NO{ + NOf (uM)Composition Nb of Poultry NO rate {+ NOf (uM)
_. - . _._. -. _.
B 8 18,87B 8 18.87
U 8 14,47U 8 14.47
V 8 7,40V 8 7.40
Comme il ressort de ce tableau, la composition de l'invention apporte une amélioration par rapport à l'eucalyptus seul.As can be seen from this table, the composition of the invention provides an improvement over eucalyptus alone.
b/ EXCRETION DES OOCYSTES APRES 5A 8 JOURS D 'INFECTIONb / EXCRETION OF OOCYSTS AFTER 5 TO 8 DAYS OF INFECTION
Les volailles sont infectées par de fortes doses d'oocystes (10 000Poultry are infected with large doses of oocysts (10,000
E. acervulena + 10 000 E. tenella). On mesure le nombre d'oocystes excrétés après 5 à 8 jours d'infection.E. acervulena + 10,000 E. tenella). The number of oocysts excreted after 5 to 8 days of infection is measured.
Les résultats figurent dans le tableau suivant :The results are shown in the following table:
Composition Nb de Volailles Taux de NO{ + NO{ (uM)Composition Nb of Poultry NO {+ NO {(uM) rate
- - _- - _
B 8 0,93B 8 0.93
U 8 2,31U 8 2.31
Comme il ressort de ce tableau, la composition de l'invention est particulièrement efficace sur l'excrétion des oocystes. As emerges from this table, the composition of the invention is particularly effective on the excretion of oocysts.

Claims

R E V E N D I C A T I O N S R E V E N D I C A T I O N S
1/ Complément alimentaire destiné à l'animal, caractérisé en ce qu'il contient en mélange : - un extrait d'Eucalyptus, un extrait de Fenugrec, un extrait de boldo.1 / Food supplement for animals, characterized in that it contains a mixture: - an extract of Eucalyptus, an extract of Fenugreek, an extract of boldo.
2/ Complément alimentaire selon la revendication 1, caractérisé en ce que l'extrait d'Eucalyptus se présente sous forme d'une huile essentielle représentant entre 8 et 15 % en poids du complément.2 / Food supplement according to claim 1, characterized in that the extract of Eucalyptus is in the form of an essential oil representing between 8 and 15% by weight of the supplement.
3/ Complément alimentaire selon l'une des revendications précédentes, caractérisé en ce que l'extrait de graine de fenugrec se présente sous forme de poudre.3 / Food supplement according to one of the preceding claims, characterized in that the fenugreek seed extract is in powder form.
4/ Complément alimentaire selon la revendication 3, caractérisé en ce que l'extrait de graine de fenugrec représente entre 10 et 30 % en poids du complément alimentaire.4 / Food supplement according to claim 3, characterized in that the fenugreek seed extract represents between 10 and 30% by weight of the food supplement.
5/ Complément alimentaire selon la revendication 1, caractérisé en ce que l'extrait de boldo représente de 10 à 20 % en poids du complément alimentaire.5 / Food supplement according to claim 1, characterized in that the boldo extract represents from 10 to 20% by weight of the food supplement.
61 Utilisation du complément alimentaire objet de l'une des revendications 1 à 5 pour la fabrication d'une composition destinée au traitement préventif ou curatif de la coccidiose du ruminant, volaille, lapin et porc. 61 Use of the food supplement which is the subject of one of claims 1 to 5 for the manufacture of a composition intended for the preventive or curative treatment of coccidiosis of ruminants, poultry, rabbits and pigs.
EP02805795A 2001-12-26 2002-12-12 Food supplement for animals Withdrawn EP1458249A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0116886A FR2833813B1 (en) 2001-12-26 2001-12-26 FOOD SUPPLEMENT FOR ANIMALS
FR0116886 2001-12-26
PCT/FR2002/004307 WO2003055328A1 (en) 2001-12-26 2002-12-12 Food supplement for animals

Publications (1)

Publication Number Publication Date
EP1458249A1 true EP1458249A1 (en) 2004-09-22

Family

ID=8871001

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02805795A Withdrawn EP1458249A1 (en) 2001-12-26 2002-12-12 Food supplement for animals

Country Status (7)

Country Link
US (2) US20040241194A1 (en)
EP (1) EP1458249A1 (en)
CN (1) CN1658765A (en)
AU (1) AU2002364990A1 (en)
CA (1) CA2470374A1 (en)
FR (1) FR2833813B1 (en)
WO (1) WO2003055328A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053420A2 (en) * 2003-11-26 2005-06-16 Hill's Pet Nutrition, Inc. Method to reduce stool odor of companion animals
FR2890535B1 (en) * 2005-09-12 2012-04-20 Adisseo Ireland Ltd COMBINATION OF BIODISPONIBLE METHIONINE WITH AT LEAST ONE ESSENTIAL OIL
CA2597371A1 (en) * 2007-06-15 2008-12-15 Reuben D. Walker A nutraceutical preparation that improves weight, weight gain and feed efficiency in animals
FR2931075B1 (en) * 2008-05-13 2010-07-30 Setubio Sas FENUGREC EXTRACT FOR THE TREATMENT OF HUMAN AND ANIMAL DISEASES INVOLVING FLAGAL PARASITES
CN101653198B (en) * 2008-08-20 2012-05-23 北京康华远景科技有限公司 Feed additives for preventing and controlling coccidiosis and preparation methods thereof
CN101744116B (en) * 2008-12-08 2012-07-25 北京康华远景科技有限公司 Feed additive for producing nutrient flavored eggs and making method thereof
US20160206654A1 (en) * 2013-09-30 2016-07-21 Furst-Mcness Company Methods and feed supplements for livestock
US9107420B2 (en) 2014-01-13 2015-08-18 Eliana Ellern Animal shampoo
CN105961860A (en) * 2016-05-23 2016-09-28 四川农业大学 Anti-coccidium block for sheep and preparation method of anti-coccidium block
CN107319134B (en) * 2017-06-14 2018-10-26 江苏隆达生物科技有限公司 A kind of feed addictive and preparation method improving animal reproduction performance and disease resistance
CN107494913A (en) * 2017-09-26 2017-12-22 陕西杨凌富仕特饲料有限公司 A kind of feed addictive using microbial fermentation tonka bean powder as protein raw materials
FR3078629B1 (en) * 2018-03-12 2020-07-31 Adisseo France Sas SAPONIN-BASED FOOD ADDITIVE FOR THE TREATMENT OF COCCIDIOSIS
BR102018076813A2 (en) 2018-12-20 2020-06-30 Suzano Papel E Celulose S A food and additive compositions, as well as uses of lignin and additive composition
CN110663839A (en) * 2019-11-04 2020-01-10 江苏隆达生物科技有限公司 Plant essential oil feed additive for preventing and treating rabbit coccidiosis and preparation method thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2298333A1 (en) * 1975-01-24 1976-08-20 Bouaziz Ely Cattle feed additive contg. fenugreek sulphur and sodium hyposulphite - protects against tuberculosis, parasites and nervous disorders
US4128640A (en) * 1976-04-14 1978-12-05 Samuel Klein Feed for poultry
US4053602A (en) * 1976-11-02 1977-10-11 Merck & Co., Inc. Compositions for treating coccidiosis containing 5-deazariboflavin and its derivatives
NO154918C (en) * 1977-08-27 1987-01-14 Bayer Ag ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.
US4218438A (en) * 1979-02-14 1980-08-19 Eli Lilly And Company Anticoccidial combinations comprising nicarbazin and the polyether antibiotics
JPS5780325A (en) * 1980-09-05 1982-05-19 Nat Res Dev Coccidial disease vaccine
US4407802A (en) * 1981-09-28 1983-10-04 Merck & Co., Inc. 6-Amidino-9-substituted benzyl purines
FR2582485A1 (en) * 1985-05-31 1986-12-05 Cornuau Claude Composition for supplementing and balancing animal feeding and method for preparing it
FR2595548B1 (en) * 1986-03-14 1989-10-27 Amann Chantal FOOD SUPPLEMENT WITH A VEGETABLE DOMINANT FOR PETS AND PARTICULARLY FOR DOGS AND CATS
US5155096A (en) * 1987-06-15 1992-10-13 Garcia Y Bellon Donato P Method for potentiation of a therapeutic agent
JPH06227999A (en) * 1993-02-03 1994-08-16 Nippon Kayaku Co Ltd Animal growth promoter, agent for reducing face odor and feed
JP3224131B2 (en) * 1993-04-07 2001-10-29 エーザイ株式会社 Immunostimulatory / infective protective agent containing two or more bacteria, egg white and garlic
JPH0746963A (en) * 1993-08-06 1995-02-21 Nippon Terupen Kagaku Kk Feed for livestock
AU4617896A (en) * 1995-02-16 1996-09-04 Maple Leaf Foods Inc Particulate feed supplement
US5707631A (en) * 1996-04-30 1998-01-13 Advanced Plant Pharmaceuticals Incorporated Therapeutic herbal composition
BR9711019A (en) * 1996-08-02 1999-08-17 Plum Kemi Prod Oil-in-water emulsion for use on human skin for cleaning, preserving or improving the condition of the skin
IES970063A2 (en) * 1997-01-31 1997-09-10 Phelim Greene Animal feed supplement composition
GB9725291D0 (en) * 1997-11-28 1998-01-28 Barrier Hygiene Ltd A disinfectant
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
US6210738B1 (en) * 1999-04-23 2001-04-03 E Excel Internatioanal Inc. Freeze-dried ginseng berry tea
US20020082279A1 (en) * 1999-10-15 2002-06-27 Neal B. Schultz Method and composition for the treatment of dermatologic diseases
US20010036488A1 (en) * 2000-01-18 2001-11-01 Syuichi Hayashi Anti-obestic composition
EP1228769A1 (en) * 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiotic regenerative composition
FR2827774B1 (en) * 2001-07-30 2005-06-24 Dolisos Lab PHARMACEUTICAL AND / OR DIETARY PREPARATIONS CONTAINING ACTIVE PLANT VEGETABLE EXTRACT AND PROBIOTIC MICROORGANISMS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03055328A1 *

Also Published As

Publication number Publication date
CN1658765A (en) 2005-08-24
FR2833813A1 (en) 2003-06-27
AU2002364990A1 (en) 2003-07-15
CA2470374A1 (en) 2003-07-10
US20040241194A1 (en) 2004-12-02
FR2833813B1 (en) 2005-08-26
WO2003055328A1 (en) 2003-07-10
US20060269624A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
Oluwafemi et al. Recent trends in the utilization of medicinal plants as growth promoters in poultry nutrition-A review
US10583164B2 (en) Compositions including ginger for the amelioration or prevention of inflammatory conditions
Distel et al. Experience early in life affects voluntary intake of blackbrush by goats
JP3080654B2 (en) Pharmaceutical compositions based on plant-derived ethereal oils for use in human and veterinary medicine
US20060269624A1 (en) Food supplement for animals
NO861673L (en) PROCEDURE FOR PROCESSING A FOOD OR ANIMAL FOOD.
FR3042713B1 (en) EFFICIENT ANTIOXIDANT COMPOSITION FROM A SYNERGISTIC VIEWPOINT FOR PETS
US20090246314A1 (en) Equine whole food supplements
EP0786944B1 (en) Poultry feed additive composition
JP2008505974A (en) Methods for inducing anxiolytic and sedative effects in animals and humans
KR101895733B1 (en) Mixed feed for companion animals
Rahal et al. Neem extract
Ntsafack et al. Post-weaning growth performances of guinea pigs (Cavia porcellus) feed on a diet containing Ipomea batatas leaves and/or Stylosanthes guianensis meal
Sharma et al. Common poisonous plants affecting livestock of Himachal Pradesh: A Review
FR2899065A1 (en) Composition useful e.g. as veterinary medicament with antioxidant action in animals, comprises food medium for animal feed and microgranules adsorbed on and/or mixed with mineral support/vegetable base
JP3274677B1 (en) Eggs with active oxygen scavenging ability and their production method
Guzman et al. Fumonisin mycotoxins: their origin and effects on livestock
EP1266578A1 (en) Feed preparation for animals, especially for poultry
WO2020002716A1 (en) Antiparasite composition containing betaine and extracts of echinacea purpurea and curcuma longa
Poppe Possible causes of fertility problems in dairy cows
WO2000072858A1 (en) Food additive composition for preventive treatment of coccidiosis
Caballero A powerful alternative to antibiotics for Aquaculture
Knight et al. Plants Affecting the Skin and Liver (16-May-2003)
Obua et al. Deaths among pigs fed sole fresh cassava by-products in humid southeastern Nigeria
Minatchy et al. Nutraceutical properties of Leucaena leucocephala, Manihot esculenta, Cajanus cajan in goat kids infected with Haemonchus contortus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 33/02 20060101ALI20090703BHEP

Ipc: A61K 36/00 20060101ALI20090703BHEP

Ipc: A23K 1/18 20060101ALI20090703BHEP

Ipc: A23K 1/16 20060101AFI20090703BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091126